Trinds

What Trinds does

TRiNDS is a specialized contract research organization (CRO) exclusively focused on clinical trials in neuromuscular and rare diseases, with particular depth in Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), Myotonic Dystrophy (DM1), and Pompe Disease. Founded in 2016 in Pittsburgh, Pennsylvania, and led by CEO Lauren Morgenroth, the firm was spun out of the Cooperative International Neuromuscular Research Group (CINRG) academic network to address the unmet need for a dedicated NMD-specific CRO. TRiNDS operates a six-service platform: Clinical Operations, Data Management, Study Measurements, Community Engagement, a standing Data Monitoring Committee (DMC/DSMB operational since 2005), and Genetic Confirmation services staffed by board-certified genetic counselors.

The company's underlying technology stack consists of regulatory-compliant clinical-trial infrastructure — electronic data capture (EDC), electronic trial master file (eTMF), and clinical trial management system (CTMS) — combined with proprietary operational assets including the long-standing NMD-focused DMC, central genetic-review protocols, and domain-specific outcome-measure training programs. TRiNDS differentiates through flexible approaches such as home-based trial visits, remote monitoring methods, and wearable activity monitoring, all anchored in deep disease knowledge rather than automation. The firm holds compliance certifications including GDPR, HIPAA, and ICH-GCP.

TRiNDS monetizes through professional-services, custom project-based contracts with biopharmaceutical sponsors and academic investigators. Pricing is quote-based and tailored to each project, typically structured as multi-year contracts. Two primary customer segments are served: biopharmaceutical companies (primary segment, including disclosed work with Italfarmaco Group on Givinostat for DMD) and academic research groups (including its coordinating-center relationship with CINRG). The company maintains a globally distributed, predominantly work-from-home team of 11–50 employees, with active trials delivered across U.S. and international sites.

Name

Trinds

Legal name

TRiNDS

Website

https://trinds.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

TRiNDS is a specialized contract research organization that runs clinical trials exclusively in neuromuscular and rare diseases, serving biopharmaceutical sponsors and academic investigators with project-based clinical operations, data management, standing DMC, and genetic confirmation services.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Neurogenetics & Rare Neurologic Diseases (HLAKAIAO)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular Cytogenetics & Genomic Variation Services (Karyotyping/FISH/aCGH/CNV) (HLAGANAJ)

Keywords

• Clinical research services
• Neuromuscular disease trials
• Rare disease CRO
• Clinical data management
• Genetic confirmation services

Headquarters

HQ city

United

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Contract Research Organization Services: TRiNDS provides solutions to pharmaceutical and biotechnology industries as well as academic investigators/groups for their neuromuscular and rare disease clinical study needs. Services include clinical operations, data management, study measurements, community engagement, data monitoring committee support, and genetic confirmation services. Revenue is generated through project-based contracts with biopharmaceutical companies and academic researchers conducting clinical trials.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

TRiNDS is a specialized contract research organization providing customized clinical trial services for neuromuscular and rare diseases, including Clinical Operations, Data Management, Study Measurements, Community Engagement, Data Monitoring Committee oversight, and Genetic Confirmation. The company serves biopharmaceutical companies and academic investigators conducting trials in Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), Myotonic Dystrophy (DM1), Pompe Disease, and other neuromuscular disorders, and acts as the coordinating center for the CINRG academic research network.

Product overview

TRiNDS is a specialized contract research organization (CRO) offering a comprehensive suite of services for neuromuscular and rare disease clinical trials. The company operates a platform-plus-specialized-services model with five core service lines (Clinical Operations, Data Management, Study Measurements, Community Engagement, and Disease/Research Knowledge) supported by strategic solutions including a standing Data Monitoring Committee (DMC) and Genetic Confirmation services. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, TRiNDS leverages experience from the Cooperative International Neuromuscular Research Group (CINRG) academic network to provide domain-specific expertise in Duchenne muscular dystrophy, Becker muscular dystrophy, and other rare neuromuscular disorders.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Operations Trial management, site selection and startup, regulatory and ethics board approvals, monitoring visits, and project management services for neuromuscular and rare disease clinical trials. Targeted at biopharmaceutical sponsors and academic investigators running neuromuscular and rare disease studies.
• Data Management Full-service data management including electronic data capture (EDC) systems, case report form design, database development, validation, quality control, and data imports/exports for neuromuscular clinical trials. Targeted at biopharmaceutical sponsors and academic investigators needing regulatory-compliant data management.
• Study Measurements Outcome measure selection, implementation, site training and qualification, equipment procurement, central data monitoring, and interpretation assistance for neuromuscular clinical trials. Targeted at sponsors needing NMD-specific outcome measure expertise.
• Community Engagement Patient outreach, advocacy, recruitment and retention strategies, educational materials development, and site support for rare neuromuscular disease clinical trials. Targeted at sponsors needing specialized recruitment in rare disease populations.
• Data Monitoring Committee (DMC) Standing neuromuscular-focused Data Safety Monitoring Board (DSMB) providing protocol review, meeting coordination, and safety monitoring for clinical trials, with members holding standing consulting agreements for continuity. Targeted at sponsors needing NMD-experienced independent safety oversight.
• Genetic Confirmation Central genetic testing review and confirmation services by board-certified genetic counselors for Duchenne muscular dystrophy, Becker muscular dystrophy, Myotonic Dystrophy, Pompe Disease, and other neuromuscular disorders. Targeted at sponsors and academic researchers requiring expert genetic confirmation across NMD trials.

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• CINRG (Cooperative International Neuromuscular Research Group)coreStrategic or Co-development PartnerTRiNDS serves as the coordinating center for CINRG, a consortium of researchers who work together on industry sponsored and academic research projects about people with neuromuscular disorders. CINRG researchers conduct important research questions for patients and families everywhere.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Premier Research: Specialty CRO historically strong in rare disease, neurology, and pediatric trials; directly comparable to TRiNDS in targeting small-to-mid biopharma sponsors with complex rare-disease programs where deep therapeutic expertise is the differentiator.
• Cato SMS: Specialty clinical research and pharmacovigilance provider with strong rare-disease and cell/gene therapy focus; comparable to TRiNDS in targeting small-to-mid biopharma running complex orphan-disease trials with high scientific-content needs.
• Worldwide Clinical Trials: Mid-size CRO with established rare disease and neuroscience franchises; competes with TRiNDS for sponsor-funded clinical operations work in orphan and specialty indications, particularly where smaller, science-led teams are preferred over tier-1 CROs.

Broad incumbents

• Parexel: Large global CRO with established rare disease and neuroscience experience; comparable to TRiNDS in serving biopharma clients running complex specialty clinical programs, though at materially larger scale and geographic footprint.
• Medpace: Mid-to-large full-service CRO with strong therapeutic specialization across multiple areas including rare diseases; comparable to TRiNDS as a sponsor-facing CRO that competes for the same biopharma clinical operations budgets, though Medpace operates at much greater scale across many indications.
• ICON plc: Top-tier global CRO (post-PRA Health acquisition) offering broad clinical operations including rare disease and neurology; comparable to TRiNDS as a sponsor-facing CRO, though ICON's scale, technology stack, and geographic reach are substantially larger.
• Syneos Health: Large biopharma solutions and clinical services organization that competes with TRiNDS for outsourced clinical operations work, including in rare and specialty indications; broader portfolio but overlapping sponsor client base.
• IQVIA: Largest global CRO with growing rare-disease and specialty therapeutic capabilities; competes with TRiNDS for biopharma clinical trial work, especially larger Phase 2/3 programs, and exerts pricing pressure on smaller specialists.

Emerging players

• Veristat: Small-to-mid clinical research organization focused on rare diseases and complex therapies for small biopharma sponsors; directly comparable to TRiNDS in business model, target sponsor segment, and reliance on therapeutic specialization rather than scale.
• Atlantic Research Group: Specialty CRO focused on rare and orphan disease clinical trials for small biopharma and biotech sponsors; directly comparable to TRiNDS in business model, target sponsor profile, and reliance on deep disease-area expertise as the primary differentiator.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xtwitter.com/trinds_nmd
• Facebookfacebook.com/trindsnmd
• LinkedInlinkedin.com/company/trinds

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Trinds